Prestige Consumer Healthcare Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 7, 2020, by Prestige Consumer Healthcare Inc. (PBH). The filing primarily serves to announce financial results for the fiscal quarter and fiscal year ended March 31, 2020, and to disclose a change in the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) referenced in the document but are not explicitly detailed in the body of this Form 8-K.
Material Changes and Corporate Governance
- Board Appointment: Dawn M. Zier was elected to the Board of Directors on May 4, 2020. She previously served as President and CEO of Nutrisystem and currently serves on the boards of The Hain Celestial Group, Inc. and Spirit Airlines.
- Committee Assignments: Ms. Zier was appointed to the Audit, Compensation and Talent Management, and Nominating and Governance Committees.
- Compensation: Ms. Zier received a one-time grant of restricted stock units with a pro-rated value of approximately $36,260. These units vest one year after the grant date, contingent on continued board membership.
Guidance, Outlook, and Risks
The Company began investor presentations on May 7, 2020, utilizing slides (Exhibit 99.2) regarding the fiscal year ended March 31, 2020. The Company expects to use this presentation, potentially with modifications, throughout the fiscal year ended March 31, 2021. The filing includes standard disclaimers stating that the information in the exhibits is not deemed "filed" under the Exchange Act and that the Company undertakes no obligation to update the information unless required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 and full-year 2020 financial results, including revenue and earnings per share.
- Examine Exhibit 99.2 (Investor Presentation) for management's outlook and guidance for the fiscal year ending March 31, 2021.
- Verify the impact of the new board member's expertise on the Company's strategic direction, particularly regarding nutrition and weight loss solutions.
- Confirm the vesting schedule and settlement terms of the restricted stock units granted to Ms. Zier.